Formal Meetings for PDUFA Products and Communication Best Practices (4of14) REdI 2018 Published 2020-05-15 Download video MP4 360p Download video MP4 720p Recommendations 33:18 Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018 3:46:10 An Introduction to the CDER Quantitative Medicine Center of Excellence 1:28:43 Modeling and Simulation to Select Oncology Dosages - Session 1 2:44:03 Modeling and Simulation to Select Oncology Dosages - Session 2 47:37 Electronic Submission of Safety Reports - Ready for Primetime 1:01:25 Osteoporosis: A Perspective for 2024 2:31:56 Modeling and Simulation to Select Oncology Dosages - Session 3 03:18 50th Biosimilar, Anti-choking Devices, New Initiative, High Blood Pressure | FDA In Your Day Ep. 4 01:36 How FDA is Using "Organ on a Chip" Technology to Improve Drug Evaluation Research | Researching FDA 00:31 An MOUD Success Story from Dr. Matthew Hahn 01:27 Dr. Matthew Hahn on Treating OUD with Medication 1:23:58 Statistical Considerations for Premarketing Risk Assessment 01:06 Prescribe with Confidence: Dr. Califf introduces FDA’s MOUD campaign for health care professionals 04:16 Total Product Lifecycle Advisory Program (TAP) Engagement with Device Developers 5:21:05 125th Meeting of the Blood Products Advisory Committee (BPAC) 6:01:40 May 22, 2024 Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee 00:31 Dr. Matthew Hahn on the Importance of Destigmatizing OUD Treatment 1:20:20 Chemistry, Manufacturing Controls (CMC) in an Investigational New Drug (IND) (7/14) REdI 2017 38:21 NDA and BLA Application Review Process (6of15) REdI Annual Conference – May 29-30, 2019 2:26:13 Redesigned Pre-Submission Meetings in GDUFA III: Benefits for ANDA Submission and Approval Similar videos 34:13 Communication Best Practices – Interacting with Regulatory Project Managers in CDER/ORO 46:00 Introduction to Investigational New Drug (IND) Applications (3/14) REdI 2017 37:56 Regulatory and Administrative Components of an IND Application (5/14) REdI 2017 00:26 Your Pre-IND Meeting, what you need to know? 11:56 The PDUFA Effect: 50% Spikes in Stocks 58:08 Preparing, Initiating, and Approaching the Pre-IND Meeting 35:24 Understanding FDA's New Intended Use Rule and its Implications 40:34 Demystifying the Investigational New Drug (IND) Application for Drugs and Biologics (3of14) REdI '18 45:22 Application Case Studies on FDA’s Action Letter Timing (16of16) GDF 2020 30:56 Panel Discussion 25:59 Questions and Panel Discussion (16of39) Complex Generics 2018 1:00:47 Study Data Submissions: Office of Vaccines Research and Review (OVRR) Data Submission – May 8, 2018 57:45 Inside the FDA: A Clinician's Guide to the Drug Approval Process 1:48:56 Public Meeting on Patient Focused Drug Development for Non Tuberculous Mycobacterial Infections Pt 1 26:13 Fast Tracking Antimicrobial Agents – FDA’s Accelerated Programs 17:27 Pre-ANDA review: Office of Pharmaceutical Quality (OPQ) (4of39) Complex Generics 2018 22:48 Navigating the World of Biosimilar User Fees- June 10, 2019 1:05:08 Cancer Moonshot in Action: Launching the Next Generation of Cancer Leaders More results